Avendaño-Reyes JM

Language: Spanish
References: 37
Page: 561-568
PDF size: 769.93 Kb.

ABSTRACT

Background: Proton pump inhibitors (PPI) are one of the most prescribed drugs around the world. They are effective for the treat- ment of all acid-related disorders. In recent years, there is a lot of information that has suggested an association between acid gastric suppression with PPI and Clostridium difficile infection. The United States Food and Drug Administration (FDA) recently warned the public and physicians about the possible association between C. difficile infection and PPI use.
Objetive: To investigate the strength of this association by analyzing literature information with the Bardford Hill model.
Material and Method: We identified relevant articles by searching PUBMED, 1970 to 2015 with the Medical Subjects Headings C. difficile infection and proton pump inhibitors.
Results: We found very low quality evidence supporting an association between PPI use and risk of C. difficile infection. This association was weakened by the presence of significant heterogeneity among the studies, unmeasured confounders and publication bias.
Conclusions: The information presented and analyzed here allows us to consider PPI use as a risk factor for C. difficile infection is a myth.

REFERENCES

1. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppression drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011-1019.

2. Leonard J, Marshall JK, Moayyedi P, et al. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102: 2047-2056.

3. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitors therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012;10;225-233.

4. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011;34;1269-1281.

5. Jonarthanan S, Ditah I, Adler DG, et al. Clostridium difficile associated diarrhea and proton pump inhibitors therapy: a meta-analysis. Am J Gastroenterol 2012;107;1001-1010.

6. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS ONE 2012;7:50836.

7. Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015;36:452-460.

8. Biswal S. Proton Pump Inhibitors and Risk for Clostridium difficile associated diarrhea. Biomed J 2014;37:178-183.

9. Barletta J, Sclar DA. Proton pump inhibitors increase the risk for hospital-aquired Clostridium difficile infection in critically ill patients. Critical Care 2014;18:714-720.

10. Drug Safety Communication- FDA Clostridium difficileassociated diarrhea can be associated with stomach acid drugs. Disponible en: http://www.fda.gov/Safety/ medWatch/SafetyInformation/SafetyAlertsforHumanmedicalProducts/ ucm290838.htm

11. Camacho-Ortiz A, Galindo-Fraga A, Rancel-Cordero A y col. Factores asociados con el desarrollo de la enfermedad por Clostridium difficile en un hospital de tercer nivel en México: estudio de casos y controles. Rev Invest Clin 2009;61:371-377.

12. Torres J, Cedillo R, Sánchez J, et al. Prevalence of Clostridium difficile and its cytotoxin in infants in Mexico. J Clin Microbiol 1984;20:274-275.

13. Ramírez-Rosales A, Cantu-Llanos E. Mortalidad intrahospitalaria en pacientes con diarrea asociada a infección por Clostridium difficile. Rev Gastroenterol Mex 2012;77:60-65.

14. Solana de Lope J, Aguilera E, Vinageras J, et al. Pseudomembranous colitis: report of four cases. Rev Gastroenterol Mex 1997;62:113-116.

15. Remes-Troche JM. Diarrea asociada con infección por Clostridium difficile, ¿es tiempo de preocuparnos en México? Rev Gatroenterol Mex 2012;77:58-59.

16. Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-68.

17. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 2010;69:543-552.

18. Mat Saad AZ, Collins N, Lobo MM, et al. Proton pump inhibitors: a survey of prescribing in a Irish general hospital. Int J Clin Pract 2005:59;31-34.

19. Niklasson A, Bajor A, Bergendal L, et al. Overuse of acid suppressive therapy in hospitalised patients with pulmonary diseases. Respirat Med 2003;97:1143-1150.

20. Scagliarini R, Magnani E, Praticò A, et al. Inadequate use of acid suppressive therapy in hospitalized patients and its implications for general practice. Dig Dis Sci 2005;50:2307-2311.

21. Ahrens D, Chenot JF, Behrens G, et al. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol 2010;66:1265-1271.

22. Avendaño JM, Jaramillo H, Rodriguez-Lomeli M y col. Inhibidores de secreción ácida gástrica para profilaxis de úlceras por estrés. Indicaciones apropiadas e inapropiadas y su impacto económico en un hospital de segundo nivel en Mexicali, B.C. Med Int Mex 2010:26:431-436.

23. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.

24. Barletta JF, El-Ibiary SY, Davis LE, et al. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc 2013;88:1085-1090.

25. Eom CS, Park SM, Myung SK, et al. Use of acid suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2010;9:257-267.

26. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011:106:1209-1218.

27. Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012;36:405-413.

28. Marcuard SP, Albernaz L, Khazanie PG, et al. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Int Med 1994;120:211-215.

29. Johnstone J, Nerenberg K, Loeb M, et al. Meta-analysis: proton pump inhibitor use and the risk of community- acquired pneumonia. Aliment Pharmacol Ther 2010;31:1165-1177.

30. Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007;26:545-553.

31. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Int Med 2010;170:784-790.

32. Williams C. Ocurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001;15:511-521.

33. Agastya G, West BC, Callahan JM, et al. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000;22:357-372.

34. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for antiinflamatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000;14:74-81.

35. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002;30:1118-1122.

36. Nerandzic M, Pultz MJ, Donskey CJ, et al. Examination of potential mechanism to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:4133-4137.

37. Swaen G, van Amelsvoort L. A weight of evidence approach to causal inference. J Clin Epidemiol 2009;62:270-277.